Avasimibe (CAS 166518-60-1), also known as PF-01472026 or avasimibe pfizer, is a selective inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). This enzyme plays a key role in cholesterol metabolism by catalyzing the esterification of free cholesterol. Because of this mechanism, avasimibe has attracted considerable interest in studies related to lipid metabolism, cardiovascular diseases, and metabolic disorders.
The compound is characterized by a clearly defined molecular formula and stable chemical properties that support reliable laboratory research. Scientists frequently analyze avasimibe in pharmacological and biochemical experiments to better understand cholesterol storage, lipid homeostasis, and cellular signaling pathways linked to metabolic regulation. Research laboratories working in pharmaceutical, biotechnology, and academic environments often buy 166518-60-1 as a reference compound for evaluating ACAT inhibition and studying lipid-associated disease mechanisms.
Application of Avasimibe
Avasimibe is widely used in biomedical research investigating cholesterol metabolism and atherosclerosis. Its ability to inhibit ACAT enzymes allows researchers to explore how cholesterol esterification affects cellular lipid accumulation and disease progression.
- Research on cholesterol metabolism and lipid regulation
- Investigation of ACAT enzyme inhibition mechanisms
- Studies related to atherosclerosis and metabolic disorders
- Reference compound for screening lipid metabolism modulators
Due to these properties, avasimibe remains a valuable molecule in experimental systems designed to evaluate potential therapies targeting cholesterol processing pathways.
In Vitro
In vitro experiments demonstrate that avasimibe effectively inhibits ACAT activity within cultured cells. This inhibition prevents the conversion of free cholesterol into cholesterol esters, resulting in reduced intracellular lipid accumulation. Researchers often use avasimibe in macrophage and hepatocyte models to analyze cholesterol trafficking, lipid droplet formation, and the molecular mechanisms controlling cholesterol homeostasis.
These cell-based studies help scientists evaluate how ACAT inhibition influences lipid metabolism and how new compounds compare with the established inhibitor PF-01472026.
In Vivo
In vivo research has shown that avasimibe influences systemic cholesterol metabolism and can reduce cholesterol ester formation in animal models. Experimental studies investigating lipid disorders frequently include avasimibe to examine its effects on plasma lipid profiles, hepatic cholesterol processing, and atherosclerotic plaque development.
Such studies provide valuable insight into how ACAT inhibition may affect metabolic pathways and cardiovascular risk factors.
Biochemical and Physiological Actions
The biochemical action of avasimibe is based on its selective inhibition of ACAT enzymes located in the endoplasmic reticulum of cells. By blocking cholesterol esterification, the compound alters lipid storage and promotes the presence of free cholesterol within cellular membranes.
This activity influences several physiological processes, including lipid transport, cellular cholesterol balance, and inflammatory signaling pathways associated with metabolic disease.
Features and Benefits of Avasimibe
Avasimibe is widely used in lipid metabolism and cardiovascular research because of its well-characterized mechanism and reproducible activity in experimental systems.
- Selective inhibitor of ACAT involved in cholesterol esterification
- Useful tool for studying lipid metabolism and atherosclerosis
- Suitable for both in vitro and in vivo experimental models
- Well-documented pharmacological activity in metabolic research
High-quality bioactive compounds are essential for modern drug discovery and biomedical investigations. Research teams rely on trusted suppliers that provide consistent chemical quality and rapid access to validated molecules supporting screening and mechanistic studies in pharmaceutical and academic laboratories.
